134 related articles for article (PubMed ID: 38455982)
1. VKH-like syndrome in the setting of Dabrafenib and Trametinib therapy for BRAF mutant metastatic melanoma: a case report.
Gunaratnam C; Muzicenco O; Sivagurunathan P; Franzco MH
J Surg Case Rep; 2024 Mar; 2024(3):rjae104. PubMed ID: 38455982
[TBL] [Abstract][Full Text] [Related]
2. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
[TBL] [Abstract][Full Text] [Related]
3. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
4. Vogt-Kayanagi-Harada-Like Uveitis Induced by Dabrafenib/Trametinib Therapy for Cutaneous Malignant Melanoma.
Kaymak NZ; Kaplan AT
Ophthalmic Surg Lasers Imaging Retina; 2023 Aug; 54(8):477-480. PubMed ID: 37535619
[TBL] [Abstract][Full Text] [Related]
5. Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report.
Kiraly P; Groznik AL; Valentinčič NV; Mekjavić PJ; Urbančič M; Ocvirk J; Mesti T
World J Clin Cases; 2022 Jul; 10(19):6536-6542. PubMed ID: 35979276
[TBL] [Abstract][Full Text] [Related]
6. Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report.
Lim J; Lomax AJ; McNeil C; Harrisberg B
Ocul Immunol Inflamm; 2018; 26(4):628-631. PubMed ID: 27892777
[TBL] [Abstract][Full Text] [Related]
7. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
8. Development of Acute Vogt-Koyanagi-Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma.
Apivatthakakul A; Kunavisarut P; Rothova A; Pathanapitoon K
Ocul Immunol Inflamm; 2020 Apr; 28(3):505-508. PubMed ID: 31161956
[No Abstract] [Full Text] [Related]
9. Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib.
Draganova D; Kerger J; Caspers L; Willermain F
J Ophthalmic Inflamm Infect; 2015; 5():17. PubMed ID: 26078801
[TBL] [Abstract][Full Text] [Related]
10. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome.
Wong RK; Lee JK; Huang JJ
Retin Cases Brief Rep; 2012; 6(4):423-6. PubMed ID: 25389947
[TBL] [Abstract][Full Text] [Related]
11. Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.
Diamantopoulos PT; Stoungioti S; Anastasopoulou A; Papaxoinis G; Gogas H
Melanoma Res; 2018 Dec; 28(6):648-651. PubMed ID: 30169430
[TBL] [Abstract][Full Text] [Related]
12. Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma.
Bellanca RF; Pinna A; Catania G; Belcastro E; Angi M; D'Amico Ricci G
Ocul Immunol Inflamm; 2023 Feb; 31(2):402-406. PubMed ID: 35113757
[TBL] [Abstract][Full Text] [Related]
13. Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04.
Amagai R; Fujimura T; Yamazaki E; Takahashi M; Tamabuchi E; Kambayashi Y; Hashimoto A; Hashimoto K; Asano Y
J Dermatol; 2024 Jun; 51(6):854-857. PubMed ID: 38111371
[TBL] [Abstract][Full Text] [Related]
14. Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma.
Obata S; Saishin Y; Teramura K; Ohji M
Case Rep Ophthalmol; 2019; 10(1):67-74. PubMed ID: 31097947
[TBL] [Abstract][Full Text] [Related]
15. [Vogt-Koyanagi-Harada syndrome: importance of rapid diagnosis and therapeutic intervention].
Bouchenaki N; Morisod L; Herbort CP
Klin Monbl Augenheilkd; 2000 May; 216(5):290-4. PubMed ID: 10863695
[TBL] [Abstract][Full Text] [Related]
16. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.
Fujimura T; Kambayashi Y; Tanita K; Sato Y; Hidaka T; Otsuka A; Tanaka H; Furudate S; Hashimoto A; Aiba S
J Dermatol; 2018 Jun; 45(6):735-737. PubMed ID: 29488243
[TBL] [Abstract][Full Text] [Related]
17. A Case of Bilateral Multifocal Choroiditis Associated with BRAF/MEK Inhibitor Use for Metastatic Cutaneous Melanoma.
Yanagihara RT; Tom ES; Seitzman GD; Saraf SS
Ocul Immunol Inflamm; 2022; 30(7-8):2005-2009. PubMed ID: 34009099
[TBL] [Abstract][Full Text] [Related]
18. Initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease presenting with unilateral exudative retinal detachment despite bilateral choroidal involvement.
AlBloushi AF; Herbort CP; Abu El-Asrar AM
Int Ophthalmol; 2021 Dec; 41(12):4187-4195. PubMed ID: 34346004
[TBL] [Abstract][Full Text] [Related]
19. Vogt-Koyanagi-Harada Disease: A Narrative Review.
Tayal A; Daigavane S; Gupta N
Cureus; 2024 Apr; 16(4):e58867. PubMed ID: 38800227
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of intravitreal dexamethasone implant in the management of «Vogt-Koyanagi-Harada-like syndrome» secondary to map kinase pathway inhibition.
Campos Polo R; García Guisado D; Rubio Sánchez C; Márquez Ivacevich NT
Arch Soc Esp Oftalmol (Engl Ed); 2020 Oct; 95(10):501-506. PubMed ID: 32593600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
